# Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

> **NCT00390234** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 63 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Female Reproductive Cancer
- Ovarian Carcinosarcoma
- Ovarian Sarcoma
- Recurrent Ovarian Epithelial Cancer
- Recurrent Uterine Sarcoma
- Stage III Ovarian Epithelial Cancer
- Stage III Uterine Sarcoma
- Stage IV Ovarian Epithelial Cancer
- Stage IV Uterine Sarcoma
- Uterine Carcinosarcoma
- Uterine Leiomyosarcoma

## Interventions

- **DRUG:** ziv-aflibercept

## Key facts

- **NCT ID:** NCT00390234
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2011-09
- **Final completion:** 2013-08
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2015-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390234, "Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00390234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*